China
Africa
Explore chapters and articles related to this topic
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Three similar case reports had been published previously (6,7,8). The patients all noted an exacerbation of eczema while using clobetasone butyrate cream and/or ointment. Patch tests were positive to the topicals and to clobetasone butyrate, tested in various concentrations. All three patients also reacted to clobetasol propionate. These were more likely co-sensitizations than cross-reactions, as the patients all had used pharmaceuticals with this corticosteroid also (6,7,8).
Vulval Itching
Published in Tony Hollingworth, Differential Diagnosis in Obstetrics and Gynaecology: An A-Z, 2015
Vulval pruritis is most commonly caused by irritant vulval dermatitis. Soaps, shampoos, and shower gels often contain detergents, which can deplete the skin’s natural oily barrier. Irritant vulval dermatitis causes localised eczematous changes, such as erythema, excoriation, fissuring, scaling, or weeping (Figs 1 and 2), with no changes to the vulval architecture. Soap substitutes and emollients are essential in the management of irritant vulval dermatitis. Short courses of moderately potent steroid ointment may be necessary (e.g. clobetasone butyrate 0.05%). Patch testing to identify potential allergens may be considered.
The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome
Published in Ocular Immunology and Inflammation, 2019
Carlo Alberto Cutolo, Stefano Barabino, Chiara Bonzano, Carlo Enrico Traverso
Clobetasone butyrate is widely available for dermatologic use but marketed for ophthalmic use only in a few countries. When compared with prednisolone phosphate, no difference in therapeutic efficacy was observed and clobetasone butyrate showed little effect on intraocular pressure when compared with dexamethasone or hydrocortisone.72 A single RCT has been conducted to study the effect of clobetasone butyrate 0.1% administered two times a day for 1 month in patients with SS. Compared to controls, patients treated with clobetasone butyrate 0.1% showed a significant improvement in corneal, conjunctival stain, and symptoms during the follow-up. The HLA-DR expression, a biomarker of inflammation, was also significantly reduced in the group treated with clobetasone.73